Oct 172017
 

via Abundant Life Wellness Center

A seasonal flu shot is a bit like a local weather forecast: Based on the conditions elsewhere and the direction of the prevailing wind, a meteorologist can give the public a pretty good idea of what to expect in the near future. Experts who track influenza’s intercontinental travels basically do the same thing.

“Epidemiologists monitor what strains of influenza are circulating in Southeast Asia. … they usually choose three or four of them, and they predict what the prevailing circulating strains will be,” said David Putnam, associate professor in the Nancy E. and Peter C. Meinig School of Biomedical Engineering.

“Usually they’re right, but sometimes they’re wrong,” Putnam said, “and it changes every year because proteins in the virus mutate.”

But certain proteins in the influenza virus remain constant year after year. And Putnam and Matt DeLisa, the William L. Lewis Professor of Engineering in the Robert Frederick Smith School of Chemical and Biomolecular Engineering, are taking one of those conserved proteins, Matrix-2 (M2), and packaging it in a nanoscale, controlled-release “capsule” in an attempt to create a quick-acting, long-lasting, multi-strain vaccine against pandemic influenza A.

The capsule is a bacterial outer membrane vesicle (OMV), which DeLisa and Putnam have developed collaboratively for several years. The OMV is a membrane-based nanostructure, in this case engineered from nonpathogenic E. coli, whose outer surface mimics the cell from which it originated.

Their paper, “A Single Dose and Long-Lasting Vaccine Against Pandemic Influenza Through the Controlled Release of a Heterospecies Tandem M2 Sequence Embedded Within Detoxified Bacterial Outer Membrane Vesicles,” appears in the journal Vaccine. First author is Hannah Watkins, Ph.D. ’17, now a postdoctoral researcher at the Massachusetts Institute of Technology.

The influenza A virus is a moving target. It changes year to year, and can morph into a pandemic – infectious across a large region – strain that can put the general population at risk. The Putnam-DeLisa team is leveraging the versatility of OMVs, which have shown promise against other deadly pathogens, to create a single-shot vaccine.

The M2 protein is found evolutionarily in the influenza sequence in birds, pigs and humans, so the group took two sequences from birds, one from pigs and one from humans, and assembled them into one multitarget antigen.

“So even if, say, the human strain mutates,” Putnam said, “we know where it came from and it’s going to look like the other two. We kind of covered all the bases.”

In testing, mice infected with the influenza A virus developed high antibody counts just four weeks after vaccination, compared with eight weeks from a typical multishot (prime/boost) vaccine regimen. And the protection was long-lasting: After six months, all of the test mice given the OMV vaccine survived a lethal influenza A infection.

Six months is approximately 25 percent of the typical life expectancy for a mouse, so Putnam thinks it is likely that this OMV-based vaccine would be long-lasting for humans, too.

“Even if we have to give a booster shot every 10 years, like tetanus, that’s still very good,” he said. “Theoretically it should last a long time.”

Additionally, since the vaccine cocktail is encapsulated in a bacterial vesicle, there’s no need for an adjuvant – an agent that’s added to most vaccines to boost the body’s immune response. The immune response is enhanced by the bacteria from which the OMV is derived.

“As a result, formulating and manufacturing of controlled-release OMVs should be more cost-effective,” DeLisa said.

Learn more: A new kind of influenza vaccine: One shot might do the trick

 

The Latest on: Multi-strain flu vaccine
  • Israeli Super-Vaccine for Flu Reported, Investors Happy
    on February 8, 2018 at 4:00 pm

    Israel Radio reported Sunday morning that an Israeli company had developed a universal vaccine for all forms of ... 1,000th swine flu death there. Nevertheless, the company says its universal multi-season/multi-strain flu vaccine will greatly enhance ... […]

  • BiondVax and European UNISEC Consortium to Host Universal Flu Vaccine Conference
    on February 8, 2018 at 4:30 am

    There is wide consensus for the urgent need to develop a broadly protective and effective influenza vaccine. BiondVax continues to lead the global effort and hopes to be the first to bring to the world a multi-strain multi-season universal flu vaccine ... […]

  • Flu Shot Clinics Ongoing as Cases Go Up
    on February 5, 2018 at 8:45 pm

    The sign pointed the way at the Niagara Falls Memorial Medical Center's Golisano Clinic, with availability of about 200 or so doses of the flu vaccine. There was a high potency variety for the very susceptible elderly and the multi strain dose for the rest ... […]

  • Could a longer-lasting flu shot be a reality in the future?
    on October 10, 2017 at 11:53 pm

    Their hope is that the new shot will be a quick-acting, long-lasting, multi-strain vaccine against influenza A, and would mean maybe just one jab would be sufficient for protection. The influenza A virus can be described as a “moving target” as it ... […]

  • Flu: Breakthrough as multi-strain vaccine raises prospect of 'universal' protection against virus
    on August 24, 2015 at 9:03 am

    Scientists have developed a flu vaccine that works against more than one strain of the influenza virus which has raised the prospect of a “universal” vaccine against all types of flu. Currently, seasonal flu vaccines are designed against specific viral ... […]

  • Universal flu vaccine 'could be available in just five years'
    on February 1, 2012 at 2:09 am

    Harnessing the immune system’s response to the peptides could produce an all-encompassing multi-strain vaccine, the scientists believe. Current flu vaccines produce an antibody response to surface molecules which alter rapidly to keep one step ahead of ... […]

  • Research May Lead to Better Flu Vaccines
    on January 2, 2007 at 4:00 pm

    The research team found hundreds of epitopes that were similar among different strains of the flu virus, and one, in particular, that appears ideal for multi-strain vaccines. More research may help scientists identify targets for vaccines that could offer ... […]

via Google News and Bing News

Other Interesting Posts

Leave a Reply

%d bloggers like this: